SCHEMBL23927463

SCHEMBL23927463

CCOC(=O)c1nnc(Cc2ccc(F)c(C)c2)[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 3/20 0.40
HDAC4 P56524 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
KMT2A Q03164 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
HPGD P15428 2/20 0.39
MEN1 O00255 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
DAO P14920 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
PDE3B Q13370 2/20 0.37
PDE3A Q14432 2/20 0.37
LMNA P02545 1/20 0.37
KCNH2 Q12809 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
ALOX15 P16050 1/20 0.37
ALOX5 P09917 1/20 0.37
MPO P05164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22272869 0.91 ALDH1A1 (0.43) HDAC4HDAC6KMT2ANPSR1HPGD
SCHEMBL30091681 0.91 ALDH1A1 (0.43) HDAC4HDAC6KMT2ANPSR1HPGD
SCHEMBL30091468 0.87 ALOX5 (0.41) KMT2ANPSR1MEN1TSHRMAPK1
SCHEMBL23927482 0.87 ALOX5 (0.41) KMT2ANPSR1MEN1TSHRMAPK1
SCHEMBL23927523 0.86 LMNA (0.40) KMT2ALMNAALOX15
SCHEMBL23927444 0.85 P2RX7 (0.42) HDAC4HDAC6HPGDALOX5ALDH1A1
SCHEMBL30091676 0.85 KMT2A (0.38) HDAC4HDAC6KMT2ANPSR1HPGD
SCHEMBL23927442 0.85 KMT2A (0.38) HDAC4HDAC6KMT2ANPSR1HPGD
SCHEMBL30091705 0.84 MMP13 (0.41) MMP13DAOMPOMMP10MMP8
SCHEMBL15964604 0.83 MEN1 (0.50) HDAC4HDAC6KMT2ANPSR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-10-07 US disclosed
EP-3901147-B1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-11-22 EP disclosed
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-26 US disclosed
CN-113166116-B Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2022-12-27 CN disclosed
EP-3901147-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-10-27 EP disclosed
CN-113166116-A Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF RIPK1, RIPK3, RIPK4 MMP13 2943/4885HDAC4 691/4885HDAC6 315/4885
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof RIPK1, RIPK3, RIPK4 MMP13 2943/4885HDAC4 691/4885HDAC6 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.